profit from every £100 of sales.
£0£100
Oxford Nanopore Technologies
£2.01-1.85% today
+40.4% in 1 year
1-year low £1.051-year high £2.35
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Oxford Nanopore Technologies sold, what it kept, and what it did with the cash.
Sales went from £199 million in 2022 to £224 million in 2025, with -£145 million of profit last year.
SalesProfit
Oxford Nanopore Technologies vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from £100 of sales | Sales growth a year | Price per £1 of profit |
|---|---|---|---|
| Oxford Nanopore Technologies | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Oxford Nanopore Technologies's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 199 | 170 | 183 | 224 | |
| 124 | 90 | 105 | 131 | |
| -98 | -169 | -152 | -155 | |
| -50 | -106 | -93 | -87 | |
| -91 | -155 | -146 | -145 | |
| -0.11 | -0.19 | -0.16 | -0.15 | |
| 62.3% | 53.3% | 57.5% | 58.6% | |
| -49.6% | -99.4% | -83.1% | -69.4% | |
| -45.8% | -91.1% | -79.8% | -64.9% |
Balance sheet
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 824 | 777 | 742 | 623 |
| Cash | 357 | 221 | 200 | 181 |
| Total debt | 34 | 42 | 46 | 42 |
| Total liabilities | 130 | 133 | 156 | 159 |
| 694 | 644 | 586 | 463 | |
| 824 | 834 | 898 | 961 | |
| -8.4% | -16.1% | -16.2% | -20.4% | |
| -13.1% | -24.0% | -24.9% | -31.3% |
Cash flow
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -64 | -137 | -110 | -71 | |
| 28 | 27 | 49 | 46 | |
| -92 | -165 | -159 | -116 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 49 | 35 | 4 | 20 |
Valuation
- –
- –
- –
- 2.5×
- 8.8×
- –
- –
- -5.9%
- -7.3%
- –
Profitability
- 58.6%
- -69.4%
- -64.9%
- –
- -20.4%
- -15.3%
- –
- –
- –
- –
Growth
- +4.1%
- –
- –
- –
- +5.3%
Financial health
- -1.6×
- 0.09
- –
- -49.0×
- 3.56
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 952
Bottom 5%of 883
Bottom 24%of 870
Bottom 17%of 985
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
31No pass
Benjamin Graham
46No pass
Philip Fisher
33No pass
Peter Lynch
35No pass
Joel Greenblatt
0No pass
Charlie Munger
35No pass
Terry Smith
34No pass
Questions about Oxford Nanopore Technologies
Is Oxford Nanopore Technologies a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Oxford Nanopore Technologies AI analysis
What does Oxford Nanopore Technologies do?
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. It is in Biotechnology, based in Oxford, United Kingdom, with 1,316 employees.
Is Oxford Nanopore Technologies stock halal?
Yes. Oxford Nanopore Technologies passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has Oxford Nanopore Technologies stock done over the past year?
Up 40.4% over the past twelve months, to £2.01. It traded between £1.05 and £2.35 and is 14.3% below its high.
Who are Oxford Nanopore Technologies's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Oxford Nanopore Technologies's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.